Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-Directed Therapy in Esophageal Cancer
NCT01333033Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jul 2011
- Primary completion
- Nov 2015
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid, carboplatin and Paclitaxel Micelles for Injection in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Cancer and Leukemia Group B. Started Jul 2011; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acidcarboplatinPaclitaxel Micelles for Injection
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01333033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01333033.